Novel dual-action prodrug triggers apoptosis in glioblastoma cells by releasing a glutathione quencher and lysine-specific histone demethylase 1A inhibitor

Martin Engel†, Yi Sing Geet†, Dale Cross†, Alan Maccarone‡, Benjamin Heng§, Amy Hulme†, Grady Smith†, Gilles J. Guillemin§, Brett W. Stringer¶, Christopher J. T. Hyland† and Lezanne Ooi†‡

†Illawarra Health and Medical Research Institute, Wollongong, New South Wales, Australia
‡School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, New South Wales, Australia
§Mass Spectrometry User Resource and Research Facility, School of Chemistry, University of Wollongong, Wollongong, New South Wales, Australia
¶Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia
†QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia

Abstract
Targeting epigenetic mechanisms has shown promise against several cancers but has so far been unsuccessful against glioblastoma (GBM). Altered histone 3 lysine 4 methylation and increased lysine-specific histone demethylase 1A (LSD1) expression in GBM tumours nonetheless suggest that epigenetic mechanisms are involved in GBM. We engineered a dual-action prodrug, which is activated by the high hydrogen peroxide levels associated with GBM cells. This quinone methide phenylaminocyclopropane prodrug releases the LSD1 inhibitor 2-phenylcyclopropylamine with the glutathione scavenger para-quinone methide to trigger apoptosis in GBM cells. Quinone methide phenylaminocyclopropane impaired GBM cell behaviours in two-dimensional and three-dimensional assays, and triggered cell apoptosis in several primary and immortal GBM cell cultures. These results support our double-hit hypothesis of potentially targeting LSD1 and quenching glutathione, in order to impair and kill GBM cells but not healthy astrocytes. Our data suggest this strategy is effective at selectively targeting GBM and potentially other types of cancers.

Keywords: apoptosis, glioblastoma, LSD1, methylation, oxidative stress.

J. Neurochem. (2019) 149, 535–550.
new targets against GBM has turned towards the contribution of epigenetic mechanisms to GBM formation and progression (Mack et al. 2015). Transcriptional activation and repression of tumorigenesis-relevant genes is influenced by local histone methylation. For example, methylation at histone 3 lysine 4 (H3K4) residues, which is associated with increased gene expression (Santos-Rosa et al. 2002; Liang et al. 2004; Schneider et al. 2004), is reduced in severe GBM cases (Liu et al. 2010). The catalysing enzymes of these non-permanent epigenetic markers are thus of particular interest for therapeutic approaches.

Lysine-specific histone demethylase 1A (LSD1) belongs to the flavin adenine dinucleotide-dependent amine oxidase family and catalyses the demethylation of monomethylated (me1) and dimethylated (me2) H3K4 residues (Shi et al. 2004; Forneris et al. 2005). In combination with transcription factors, such as repressor element 1-silencing transcription factor, LSD1 activity and the removal of H3K4 methylation are associated with gene repression (Ooi and Wood 2007). In concert with reduction in H3K4 methylation, GBM cells have increased LSD1 protein levels (Singh et al. 2011; Sareddy et al. 2013; Zheng et al. 2015), with evidence for the functional involvement of LSD1 in GBM proliferation (Suvà et al. 2014). Positive results from pharmacological inhibition of LSD1 in other tumours with increased LSD1 expression, such as leukaemia, lung and breast cancers (Fiskus et al. 2014; Kumarasinghe and Woster 2014; Murray-Stewart et al. 2014; Mohammad et al. 2015), indicate a promising treatment potential for GBM by targeting LSD1 inhibition.

To increase the prospective success of a LSD1 inhibitor-based GBM drug, employment of a cancer-selective mechanism is needed to reduce undesired effects in healthy tissue. Cancer cells produce higher levels of reactive oxygen species (ROS), including H2O2, than non-cancerous cells (Reuter 2010). Transcriptional activation and repression of tumorigenesis-relevant genes is influenced by local histone methylation. For example, methylation at histone 3 lysine 4 (H3K4) residues, which is associated with increased gene expression (Santos-Rosa et al. 2002; Liang et al. 2004; Schneider et al. 2004), is reduced in severe GBM cases (Liu et al. 2010). The catalysing enzymes of these non-permanent epigenetic markers are thus of particular interest for therapeutic approaches.

Lysine-specific histone demethylase 1A (LSD1) belongs to the flavin adenine dinucleotide-dependent amine oxidase family and catalyses the demethylation of monomethylated (me1) and dimethylated (me2) H3K4 residues (Shi et al. 2004; Forneris et al. 2005). In combination with transcription factors, such as repressor element 1-silencing transcription factor, LSD1 activity and the removal of H3K4 methylation are associated with gene repression (Ooi and Wood 2007). In concert with reduction in H3K4 methylation, GBM cells have increased LSD1 protein levels (Singh et al. 2011; Sareddy et al. 2013; Zheng et al. 2015), with evidence for the functional involvement of LSD1 in GBM proliferation (Suvà et al. 2014). Positive results from pharmacological inhibition of LSD1 in other tumours with increased LSD1 expression, such as leukaemia, lung and breast cancers (Fiskus et al. 2014; Kumarasinghe and Woster 2014; Murray-Stewart et al. 2014; Mohammad et al. 2015), indicate a promising treatment potential for GBM by targeting LSD1 inhibition.

To increase the prospective success of a LSD1 inhibitor-based GBM drug, employment of a cancer-selective mechanism is needed to reduce undesired effects in healthy tissue. Cancer cells produce higher levels of reactive oxygen species (ROS), including H2O2, than non-cancerous cells (Reuter et al. 2010), while being able to withstand 10- to 100-fold higher H2O2 concentrations (Hagen 2010), while being able to withstand 10- to 100-fold higher H2O2 concentrations (Hagen 2010), while being able to withstand 10- to 100-fold higher H2O2 concentrations (Hagen 2010). Both these prodrugs and other anti-cancer drugs therefore directly or indirectly target the GSH mechanism to further elevate intracellular ROS and kill their target cells (Alexandre et al. 2006; Badr et al. 2013; Kohsaka et al. 2013; Noh et al. 2015). However, cancer-cell-selective prodrugs based on the common LSD1 inhibitor trans-2-phenylcyclopropylamine (2-PCPA/tranylcypromine) are almost unexplored to date. The group of Suzuki made a seminal contribution in this field, with their development of a prodrug that conjugated 2-PCPA with the anti-oestrogen agent 4-hydroxytamoxifen (Ota et al. 2016). Their prodrug selectively released 4-hydroxytamoxifen in the presence of LSD1, which has increased expression in breast cancer tissue (Lim et al. 2010). As such, the prodrug was able to inhibit the growth of breast cancer cells via inhibition of LSD1 and oestrogen receptor alpha, while not exhibiting cytotoxicity towards normal cells.

Advancing on existing (pro)drugs that focus primarily on amplification of oxidative stress, we have developed a dual-action prodrug that releases the LSD1 inhibitor 2-PCPA and the GSH scavenger QM following H2O2 activation via an aryl boronate trigger. This dual-action prodrug was more effective than either 2-PCPA or QM precursors alone or when applied together as independent compounds. The quinone methide phenylaminocyclopropane prodrug (Q-PAC) impaired key GBM cell behaviours and triggered cell apoptosis through its hybrid action in several primary and immortal GBM cell cultures. Our data support the double-hit hypothesis of targeting LSD1 and scavenging GSH, in order to selectively impair and ultimately kill GBM cells over healthy astrocytes.

Materials and methods

Chemical synthesis and analysis
All reactions were conducted in oven-dried glassware under nitrogen atmosphere. Reaction solvents were dried by passing through a column of activated alumina and then stored over 4 Å molecular sieves. Progress of reactions was tracked by thin-layer chromatography (TLC) and was performed on aluminium-backed silica gel sheets (Grace Davison, Columbia, MD, USA, UV254). TLC plates were visualized under UV lamp at 254 nm and/or by treatment with one of the following TLC stains: phosphomolybdic acid stain: phosphomolybdic acid (10 g), absolute EtOH (100 mL); Potassium permanganate stain: KMnO4 (1.5 g), 10% NaOH (1.25 mL), water (200 mL); Vanillin stain: Vanillin (15 g), concentrated H2SO4 (2.5 mL), EtOH (250 mL). Column chromatography was performed using silica gel (40–75 μm) as the solid phase. For nuclear magnetic resonance (NMR) spectroscopy, analytes were dissolved in deuterated chloroform unless stated otherwise. NMR spectra for each compound were collected from one of the following instruments: Mercury 2000 spectrometer operating at 500 and 125 MHz for 1H and 13C NMR, respectively, or a Varian spectrometer operating at 300 and 75 MHz for 1H and 13C NMR, respectively. NMR data are expressed in parts per million (ppm) and referenced to the residual chloroform in the deuterated solvent (7.26 ppm for 1H NMR and 77.16 ppm for 13C NMR). The following abbreviations are used to assign the multiplicity of the 1H
Novel prodrug reduces survival of glioblastoma cells

NMR signal: s = singlet; bs = broad singlet; d = doublet; t = triplet; q = quartet; quint = quintet; dd = doublet of doublets; m = multiplet. For mass spectrometry analyses were dissolved in HPLC grade methanol. High-resolution mass spectra were collected from a Waters Xevo G1 QTOF mass spectrometer (Rydalmere, NSW, Australia) LTQ Orbitrap XL (ESI). Infrared spectra were obtained from a Shimadzu IRAfinity-1 Fourier transform infrared spectrophotometer with an ATR attachment (Shimadzu, Kyoto, Japan). The log BB value for Q-PAC was calculated using ChemDraw Professional 15.0 (PerkinElmer, Hopkinton, MA, USA).

Synthesis details of Q-PAC (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl (2-phenylcyclopropyl)carbamate)

Triethylamine (0.4 mL, 290.4 mg, 2.87 mmol, 1.2 equiv) and diphenylphosphorinazide (0.58 mL, 742.4 mg, 2.70 mmol, 1.1 equiv) were added to a solution of 2-phenylethene-1-carboxylic acid (399.6 mg, 2.46 mmol, 1 equiv) and 4-(hydroxymethyl)phenylboronic acid pinacol ester (637.6 mg, 2.72 mmol, 1.1 equiv) in dry dioxane (5 mL). The reaction solution was heated at 105°C for 4 h then cooled to 22°C. Solvent was evaporated under reduced pressure and the compound was purified by column chromatography (25% ethyl acetate in hexane). The title compound was obtained as a colourless oil (513.6 mg, 1.31 mmol) in 53% yield.

1H NMR (500 MHz, CDCl3): δ 7.79 (d, J = 7.5 Hz, 2H), 7.33 (d, J = 7.5 Hz, 2H), 7.25–7.23 (m, 2H), 7.17–7.09 (m, 3H), 5.23 (bs, 1H), 5.12 (s, 2H), 2.75 (bs, 1H), 2.06 (bs, 1H), 1.33 (s, 12H) and 1.18 (bs, 2H) ppm. 13C NMR (75 MHz, CDCl3): δ 156.8, 140.5, 139.5, 135.1, 128.4, 127.2, 126.6, 83.9, 66.7, 32.7, 24.9 and 16.2 ppm. IR (Neat): 3318, 2977 and 1706 cm⁻¹. High resolution mass spectrometry (HRMS) (ESI) Found: M⁺, 393.2102. C23H28BNO4 requires M⁺, 393.2111.

Synthesis of quinone methide aminocyclopropane (QAC) is included in the supplemental methods. 4-(hydroxymethyl) Phenylboronic acid pinacol Ester was purchased from AKScientific (AMTB135; Union City, CA, USA), 2-PCPA from Sigma-Aldrich (P8511; Castle Hill, NSW, Australia).

Prodrug activation assay

Following the procedure of Hagen et al. (2012) a solvent system of 9 : 1 acetonitrile : water (v : v) was used to prepare a solution of Q-PAC and triethylamine (both 0.9 mM) for activation with hydrogen peroxide (9 mM). At 5 min intervals up to 30 min aliquots were diluted 90-fold in solvent for analysis via electrospray ionization mass spectrometry on either a Thermo LTQ ion-trap or LTQ Orbitrap XL. Both utilized an Ion Max ESI source operated in positive mode with nitrogen as the desolvation gas. The following settings were used between passages 8 and 15, absence of mycoplasm confirmed every 3 months (MycoAlert; Lonza, Basel, Switzerland). The U87MG line is listed by ICLAC for contamination of the ATCC version. We used the ECACC version in this study, which shows to be not identical to the ATCC version, or was contaminated with other cell lines based on our short tandem repeat profiling analysis.

Primary glioblastoma cultures provided by the Brain Cancer Research Unit of the QIMR Berghofer Medical Research Institute (2015) were established from untreated biopsy samples of different glioblastoma subtypes (Verhaak et al. 2010; Day et al. 2013) (SJH1: 72 years male, neural; RN1: 56 years male, classical; JK2: 75 years male, proneural). Approval for this study was obtained from the Human Research Ethics Committee of The University of Wollongong (HE16/324). Cells were maintained in Knockout-Dulbecco’s modified Eagle’s medium/F12 (Life Technologies, #12660-012) with StemPro supplement (Life Technologies, #A10508-01), human epidermal growth factor (20 ng/mL) (Life Technologies, #PHG0314) and human FGF2 (10 ng/mL) (Life Technologies, #PHG0024), and seeded at 35 000 cells/cm² on matrigel (Corning, NY, USA, #354277, 1/100 dilution). Cells were used between passages 5 and 13 in 2015 and 2016, absence of mycoplasm confirmed every 3 months (MycoAlert, Lonza).

Human astrocyte cultures were generated from human foetal brain tissue, which was obtained from 17- to 20-week-old foetuses collected after therapeutic termination following informed consent. Approval for this study was obtained from the Human Research...
Ethics Committee of Macquarie University (#5201200411). Written informed consent was obtained from the participants. Astrocytes were prepared using a protocol adapted from previously described methods (Guillemin et al. 1997) with slight modification. One gram of brain was washed thrice with phosphate-buffered saline (PBS) containing 1% antibiotic/anti-mycotic to remove contaminating blood. Visible blood vessels were removed with sterile scissors. Next, the tissue was placed in RPMI medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum and 2% antibiotic/anti-mycotic and dissociated mechanically by pipetting with a serological pipette. After 1 week in culture, the medium was removed and the culture was washed with PBS to remove unattached tissue fragments followed by addition of fresh medium. Once confluent, the culture was subjected to successive passage with trypsin-EDTA (0.25%) (Life Technologies) to remove contaminating cells. The tissue was placed in RPMI medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum and 2% antibiotic/anti-mycotic to remove contaminating blood. Visible blood vessels were removed with sterile scissors. For experiments, cells were seeded at 20 000 cells/cm² for experiments. Cells were used between passages 2 and 5 in 2016, and absence of mycoplasma was confirmed after collection (MycoAlert, Lonza).

Confluence assay
Culture confluence was monitored in 96-well plates (Greiner Bio-One, Kremsmünster, Austria) every 2 h using an IncuCyte Zoom (Essen Bioscience, Ann Arbor, MI, USA) at 10× magnification (1.22 µm/pixel resolution) with three images per well. Pre- and post-treatment confluence was quantified through the inbuilt basic analyser algorithm (Essen Bioscience) adjusted to the individual morphology of each culture type.

Migration assay
For migration assays, cells were seeded into ImageLock 96-well Plates (Essen Biosciences) and maintained until 70% confluent. The 700–800 µm scratch wounds were made in each well using the 96 well WoundMaker (Essen Biosciences) directly prior to drug treatment. Plates were imaged every 2 h and migration into the wound area was quantified using the inbuilt Scratch Wound algorithm (Essen Biosciences), adjusted to the individual morphology of each culture type.

Invasion assay
Cell invasion was examined in real time using the xCELLigence RTCA DP System (Roche Applied Science, Penzberg, Germany). The xCELLigence system (Roche Applied Science) allows continuous quantitative monitoring of cellular behaviour including invasion by measuring electrical impedance at a porous membrane (por size 8 µm). U87 cells were seeded at 22 500 cells/well into specialized two-layer cell invasion and migration plates coated with 20 µL matrigel (Corning, 1 : 30 dilution) and cultured without FBS for 24 h in the presence or absence of Q-PAC. Lower layer wells were filled with Dulbecco’s modified Eagle’s medium/F12 with 10% FBS as chemoattractant. Invasion was continuously monitored in real time over a period of 24 h. Data analysis was carried out using RTCA Software 1.2.1 (Roche Applied Science) supplied with the instrument.

Apoptosis assay
For apoptosis assays, the culture media were supplemented with caspase 3/7 NucView 488 enzyme substrate (2.5 µM final concentration; Biotium, Fremont, CA, USA, #10402) 2 h prior to drug treatment. Phase-contrast and fluorescent images were captured using an IncuCyte Zoom (green emission/excitation at 460 nm/524 nm) at 2 h intervals and 10× magnification. Caspase substrates were quantified using the inbuilt basic analyser algorithm (Table 1) from a minimum of three images per well and time point.

Cell viability assay
Culture viability was assessed with the resazurin-based Presto Blue cell viability reagent (Life Technologies, #A13261) according to the manufacturer’s instructions (2 h incubation) and quantified on a FLUOstar Optima (BMG Labtech, excitation/emission 540 nm/580 nm).

Immunocytochemistry
Cultures were fixed (4% paraformaldehyde, 15 min) and blocked (5% goat serum, 1 h) before incubation with MCM2 polyclonal rabbit antibody [Cell Signaling Technology, Beverly, MA, USA, #4007, RRID:AB_2142134, 1 : 500 in 5% bovine serum albumin (BSA)] overnight at 4°C. This was followed by incubation with goat anti-rabbit IgG conjugated to Alexa 488 (Life Technologies, #A11008, RRID:AB_143165, 1 : 1000, 1% BSA) for 1 h at 22°C and reddot2 (Biotium, #40061-1, 1/200) as a nuclear counterstain. Images were captured on an Incucyte Zoom in phase-contrast, green and red (emission/excitation 585 nm/635 nm) at 20× magnification with three images per well. The fraction of MCM2-positive cells was determined through automatic counting of reddot2 and MCM2-positive cells per image (see Table 1 for mask parameters).

Western blot
For histone modification quantification, cultures were lysed in triton extraction buffer (PBS containing 0.5% Triton X 100 (v/v), 1% protease inhibitor cocktail (P8340-1ML; Sigma-Aldrich) and 0.02% (w/v) NaN3) and histones extracted in 0.2 M HCl at 4°C over 16 h. Reduced samples were separated on 15% polyacrylamide gels and transferred onto polyvinylidene difluoro membranes (Millipore Corporation, Bedford, MA, USA). Membranes were immunoblotted at 4°C over 1 h for monomethylated H3K4 (5% milk block; Abcam, Cambridge, UK, #ab8895, RRID:AB_306847, 1 : 10 000 in 1% BSA), dimethylated H3K4 (5% milk block; Abcam, #ab7766, RRID:AB_2560996, 1 : 10 000 in 1% BSA) and acetylated H4 (3% milk block; Millipore #06-866, RRID:AB_310270, 1 : 4000 in 3% milk) followed by goat anti-rabbit IgG-horseradish peroxidase (Millipore, #AP307P, RRID:AB_11212848, 1 : 2500 in 1% milk) and detected with chemiluminescence. LSD1 expression was quantified in whole-cell lysates, separated on Criterion TGX Stain-Free Precast Gels (4–20%; Bio-Rad Laboratories, Hercules, CA, USA, #567-8095) and transferred onto polyvinylidene difluoro membranes. Total protein loading was quantified by UV imaging of trihalo transferred from the gels. Membranes were immunoblotted at 4°C over 16 h for LSD1 (5% milk block; Cell Signaling Technology, #C69G12, RRID:AB_2070132, 1 : 1500 in 5% milk), followed by goat anti-rabbit IgG-horseradish peroxidase (Sigma, St Louis, MO, USA, #A0545, RRID:AB_257896, 1 : 3000 in 2.5% milk) and detected by chemiluminescence.

GSH assay
Reduced GSH of cell lysates was measured with a fluorometric kit, according to the manufacturer’s instructions (Abcam, #ab138881)
and fluorescence intensity monitored on a FLUOstar Optima (excitation/emission 490 nm/520 nm). Sample GSH concentration was determined through a serial-diluted GSH calibration curve (150 nM to 20 μM).

**ROS quantification**

Oxidative stress in live cultures was assessed with CellROX Green (Life Technologies, #C10444), which remains non-fluorescent until oxidized by intracellular ROS. The fluorescent signal intensity is proportional to the levels of intracellular free radicals. Cultures were plated in black optical bottom plates (Thermo Fisher, #NUN165305) and incubated in CellROX Green for 30 min after treatment, followed by 2× PBS washes prior to imaging. Images were captured on an Incucyte Zoom in phase contrast and green at 20× magnification (0.61 μm/pixel resolution) with three images per well. Mean Green Intensity was normalized to culture confluence for each image.

**Blinding and statistical analysis**

Experimenter conducting the sample analysis for the GSH assay and western blot assays were blinded to the sample treatment details. Confluence, migration and caspase substrate experiments were automatically quantified through standardized algorithms and therefore not blinded. No randomization was performed to allocate samples in this study. There were no differences in sample size between the beginning of the experiments and their conclusion. This study was not pre-registered.

Analyses were performed using Graphpad Prism (GraphPad Software Inc., San Diego, CA, USA). Treatment effects were assessed using one-way or two-way analysis of variance (ANOVA) as relevant, followed by Bonferroni’s multiple comparisons test where appropriate. All cell culture experiments were conducted with at least three independent biological replicates and at least two technical replicates each. Significance was accepted at \( p < 0.05 \) and data presented as mean ± standard error of mean (SEM) for biological replicates. Number of replicates (\( n \)) in figure legends indicates independent experiments, with averages of technical replicates within each experiment.

**Results**

**Design and synthesis of Q-PAC**

The prodrug Q-PAC was designed so that it would simultaneously release the LSD1 inhibitor 2-PCPA and QM in the presence of high concentrations of \( \text{H}_2\text{O}_2 \). Q-PAC was synthesized using a Curtius rearrangement as the key step and its chemical structure assigned by NMR and mass spectrometry (Fig. 1a and Figure S1). The presence of the carbamate linkage in Q-PAC was confirmed by a \( ^{13}\text{C} \) resonance at 156.8 ppm (Figure S1a) and the four methyl groups of the pinacol boronic ester were observed as a 12H singlet at 1.33 ppm in \( ^1\text{H} \) NMR (Figure S1b). This spectral data, in combination with a shift of the methylene protons from 4.72 ppm in the starting 4-(hydroxymethyl) phenylboronic acid pinacol ester to 5.12 ppm in Q-PAC provided confirmation that the coupling of the two active fragments of the prodrug had taken place. Using the same route we also prepared control compound QAC, which would generate quinone methide like Q-PAC, but releases LSD1 inactive cyclopropylamine in place of 2-PCPA. Similar to Q-PAC, the formation of QAC was indicated by the OCH2 signal at 5.11 ppm in \( ^1\text{H} \) NMR (Figure S2a) and carbamate signal at 157.0 ppm in \( ^{13}\text{C} \) NMR (Figure S2b). In QAC the aminocyclopropane-generating fragment lacks a phenyl group, which is essential for LSD1 inhibition, and QAC is therefore used as a control to demonstrate that the QM and LSD1 inhibitor components of Q-PAC act synergistically.

**Q-PAC is activated by hydrogen peroxide**

It was envisaged that prodrug Q-PAC activation with \( \text{H}_2\text{O}_2 \) would yield QM and 2-PCPA (Fig. 1a). In the absence of GSH, QM can react with 2-PCPA to yield adduct QMA1, which can then further react with another QM to form adduct QMA2 (Fig. 1a). We used positive-mode electrospray ionization mass spectrometry (+ESI-MS) to examine this activation process. Prior to \( \text{H}_2\text{O}_2 \) addition to a Q-PAC solution a signal detected at \( m/z \) 416 is assigned to [Q-PAC + \( \text{Na}^+ \)] (Fig. 1b). Under identical instrument conditions the appearance of \( m/z \) 107 and 134 following 5 min treatment with \( \text{H}_2\text{O}_2 \) indicates the presence of initial products QM and 2-PCPA, respectively (Fig. 1b). Longer reaction times (Fig. 1b, 10 min and 25 min) show further relative increase in QM and 2-PCPA and production of QMA1 and QMA2 adducts evidenced by \( m/z \) 240 and 346 signals respectively. These results are consistent with the activation mechanism and adduct formation illustrated in Fig. 1(a). Experiments were repeated on a LTQ Orbitrap XL for high-resolution mass analysis to further support assignment. Figure 1(a) includes the exact mass for each compound and the corresponding errors calculated using the accurate masses.

---

**Table 1** Mask parameters for Incucyte Basic analyser image analysis

| Targets       | Channel | Exposure (ms) | Background correction | Edge sensitivity | Minimum particle size (µm²) | Maximum particle size (µm²) |
|---------------|---------|---------------|-----------------------|-----------------|----------------------------|-----------------------------|
| Caspase 3/7   | Green   | 400           | Top-Hat (10 µm, 2 GCU)| 0               | 10                         | ∞                           |
| Substrates    |         |               |                       |                 |                            |                             |
| MCM2          | Green   | 400           | Top-Hat (20 µm, 0.4 GCU)| 0               | 7                          | ∞, maximum eccentricity: 0.96 |
| Reddot2       | Red     | 800           | Top-Hat (20 µm, 0.3)  | -11             | 15                         | ∞                           |
Boronate trigger 2-PCPA detected by MS in the absence of GSH.

Antioxidant scavenger LSD1 inhibitor

GBM Apoptosis

© 2018 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry, J. Neurochem. (2019) 149, 535–550
acquired from averaged Orbitrap analyses (data not shown); all errors fall within 2 ppm.

The prodrug Q-PAC reduces migration and viability of U87 glioblastoma cells
To investigate the two-pronged approach of Q-PAC against GBM, we first explored its anti-cancer properties in the immortal U87 cell line, commonly used to assess novel GBM treatments. Q-PAC treatment dose dependently reduced U87 confluence within 48 h ($F(7,42) = 73.94, \ p < 0.0001$; Fig. 2a). Q-PAC treatment also reduced the migration ($F(6,13) = 16.93, \ p < 0.0001$; Fig. 2b) and invasion through matrigel ($F(4,14) = 5.324, \ p = 0.0081$, Figure S3e) of U87 cells, and reduced viability after 48 h treatment ($F(6,28) = 9.47, \ p < 0.0001$, Figure S3f). Cells responded within 4 h to Q-PAC, showing a prominent change in morphology (Fig. 2c) and migration at concentrations above 1 $\mu$M.

Fig. 1 Quinone methide phenylaminocyclopropane (Q-PAC) is activated by hydrogen peroxide (a) Activation of Q-PAC by hydrogen peroxide liberates quinone methide (QM) and trans-2-phenylcyclopropylamine (2-PCPA). In the absence of glutathione (GSH), subsequent formations of adducts QMA1 and QMA2 were detected by MS. (b) (+) ESI-MS data were collected at selected times after Q-PAC treatment with hydrogen peroxide. Sodiated Q-PAC resulting from analysis of the untreated prodrug is labelled in the time-zero spectrum at m/z 416. Peaks corresponding to activation products and adducts shown in panel (a) are also labelled. All other peaks have been accounted for as background with the exception of m/z 306. Accurate mass data (not shown) support assignment to the phenol derivative of Q-PAC (sodium adduct), which is the structure obtained by boronate oxidation prior to breakdown to QM and 2-PCPA.

Fig. 2 Quinone methide phenylaminocyclopropane (Q-PAC) impairs mobility of primary glioblastoma (GBM) cells but not healthy astrocytes. Algorithm-based confluence ($n = 6$) and 2D migration ($n = 4$) analysis of phase-contrast microscope images of GBM cultures (a–f) and primary human astrocytes (g–i) treated with Q-PAC. Data represent mean ± SEM, *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$ compared to vehicle control. (c, f, i) Representative images of U87 cultures treated with Q-PAC. Cultures treated with vehicle (EtOH) or 100 $\mu$M Q-PAC were captured in phase-contrast images 24 h after treatment at 10× magnification (scale bar = 50 $\mu$m).
To identify the contribution of the distinct components of Q-PAC to the observed responses, we assessed the need for QM (using 2-PCPA) and the requirement for LSD1 inhibition (using a phenyl-free form of Q-PAC (QAC) that would release QM and non-LSD1 inhibitor cyclopropyl-lamine (CPA)). Neither 2-PCPA, CPA nor QAC affected the culture viability (Figure S4b), confluence (Figure S4c–e) or migration ability (Figure S4f–h) at concentrations up to 300 μM for up to 48 h. These data demonstrate that combining QM with 2-PCPA provides the resulting compound with anti-cancer properties, which neither of the individual components possesses.

Q-PAC shows higher selectivity for glioblastoma cells over healthy astrocytes

To probe for the selectivity of Q-PAC against GBM cells, we evaluated the treatment response in primary GBM cultures and primary cerebral astrocyte cultures (human and mouse). The GBM cultures were grown from untreated biopsy samples of three different GBM subtypes (RN1: classical, JK2: proneural, SJH1: neural), which have been characterized previously (Day et al. 2013). Q-PAC dose dependently reduced the culture confluence in the primary GBMs (p < 0.001 for each line, Fig. 2d and Figure S3a and c), and impaired migration in the scratch wound assay (p < 0.001 for each line, Fig. 2e and Figure S3b and d). While the three primary GBMs show different proliferation and migration rates, Q-PAC treatment impaired both characteristics at concentrations above 10 μM. GBM culture viability dropped within 48 h of Q-PAC treatment at concentrations of 30 μM and above (Figure S3f). Importantly, the potent LSD1 inhibitor Triazole 6 (Kutz et al. 2014) had no effect on viability, confluence or caspase activity in primary GBM RN1 cells, and only reduced migration at 100 μM (Figure S5). In contrast to the GBM cultures, healthy astrocytes treated with Q-PAC at concentrations up to 300 μM for 48 h showed no reduction in cell viability (F(6,53) = 0.56, p = 0.76; Figure S3f), or a change in their migratory behaviour (F(6,12) = 0.47, p = 0.82; Fig. 2h). Confluence of primary astrocyte cultures differed following Q-PAC treatment (F(6,38) = 15.3, p < 0.0001; Fig. 2g), at 30 μM Q-PAC (80.1% of vehicle after 48 h, p < 0.001; Fig. 2g), but to a lesser extent than for any of the GBM cultures at the same concentration (RN1: 32.7%, JK2: 64.6% and SJH1: 62.7% of vehicle). These results demonstrate the higher vulnerability of GBM cells to Q-PAC treatment compared to healthy astrocytes in vitro.

Q-PAC causes apoptosis through GSH reduction following H3K4 methylation

Q-PAC combines the LSD1 inhibitor 2-PCPA with the glutathione scavenger QM. While GBM cultures reacted strongly to Q-PAC treatment, neither 2-PCPA nor QAC treatment resulted in such a response. We therefore investigated the mechanisms underlying the Q-PAC treatment effect, whether it affects the epigenetic profile of histones or performs its functions through other mechanisms.

Q-PAC increases H3K4 mono and dimethylation without affecting H4 acetylation

Q-PAC was designed to be selective for GBM over healthy cells via LSD1 inhibition as increased LSD1 protein levels have been observed in GBM (Singh et al. 2011; Sareddy et al. 2013; Zheng et al. 2015). We assessed the LSD1 inhibition properties of Q-PAC, in comparison to 2-PCPA and the potent LSD1 inhibitor Triazole 6, showing that Q-PAC has a similar LSD1 inhibition profile as 2-PCPA (Figure S6). We consequently quantified LSD1 levels in our cultures. In line with published results, the protein expression levels differed between culture types (F(5,12) = 17.24, p < 0.0001; Figure S7a and b), with RN1 and SJH1 cultures expressing higher levels of LSD1 compared to healthy astrocytes, while U87 and JK2 expression levels did not differ from healthy astrocytes. We quantified H3K4 mono (me1) and dimethylation (me2), as well as H4 pan acetylation, after treating U87 (low LSD1 levels) and primary RN1 (high LSD1 levels) cultures for 4 h, as changes in migration and confluence were observed within 48 h in response to Q-PAC treatment (Fig. 2). In U87 cells Q-PAC had no effect on H3K4me1 (F(5,18) = 1.024, p = 0.43; Fig. 3a), H3K4me2 (F(5,12) = 0.25, p = 0.93; Fig. 3a) or H4 acetylation (F(5,17) = 1.13, p = 0.38; Fig. 3a). In primary glioblastoma RN1 cells, however, 4 h of Q-PAC treatment showed a concentration-dependent effect on H3K4me1 (F(5,12) = 3.18, p = 0.05; Fig. 3b and c), H3K4me2 (F(5,12) = 2.74, p = 0.07; Fig. 3b and c) but not pan H4 acetylation (F(5,12) = 1.51, p = 0.26; Fig. 3b and c). Both me1 and me2 of H3K4 peaked at 10 μM Q-PAC, while not differing to control levels at lower or higher concentrations (Fig. 3b). When assessing the selectivity of Q-PAC for GBM, we found that 10 μM Q-PAC after 4 h did not affect H3K4me2 (t = 0.26, df = 6, p = 0.814; data not shown) in healthy astrocytes (H3K4me1 was not detected in the healthy astrocytes).

Q-PAC triggers concentration-dependent caspase 3/7 activity increase in GBM cells

LSD1 inhibitors have been shown to cause cell cycle arrest in breast cancer cells (Pollock et al. 2012). We therefore investigated whether cell cycle arrest is contributing to the reduction in cell viability and confluence observed in the GBM cultures after Q-PAC treatment. After quantifying the expression of minichromosome maintenance 2 (MCM2), part of the DNA replication machinery that is only expressed in proliferating cells (Williams and Stoeber 2007), we found that 48 h of Q-PAC treatment did not alter the proportion of MCM2-positive U87 or primary...
GBM cells (Figure S7c). Thus, the reduction in viable cells appears not to be caused by driving cancer cells out of the cell cycle.

Apoptosis is a possible alternative explanation for the reduction in cell viability after Q-PAC treatment, especially as increased apoptosis following the inhibition of LSD1 has been shown in colon and blood cancer cells (Wen et al. 2012; Ding et al. 2013). To assess whether Q-PAC treatment results in apoptosis, we monitored caspase 3/7 activity in treated GBM cells and healthy astrocytes. Q-PAC dose dependently increased caspase 3/7 activity in U87 (F(6,11) = 24.30, p < 0.0001; Fig. 4a), RN1 (F(5,22) = 6.2, p = 0.001; Fig. 4b), SJH1 (F(6,7) = 4.83, p = 0.028; Figure S7d) and JK2 (F(5,6) = 5.7, p = 0.027; Figure S7e) cultures, consistent with an increase in apoptosis in these cell types, without affecting caspase 3/7 activity in healthy astrocytes (F(5,12) = 2.67, p = 0.08; Fig. 4c).

Q-PAC reduces GSH levels in GBM cells

Work by Noh et al. (2015) shows that an increase in caspase 3/7 activity in cancer cells can be the result of GSH depletion through scavengers such as QM, a component of Q-PAC (Fig. 1). We consequently quantified GSH and ROS levels following Q-PAC treatment for 4 h, as this time point reflects the onset of treatment effects on confluence and migration (Fig. 2). GSH levels dose dependently decreased in U87 and RN1 cells, but not in healthy astrocytes (Fig. 4d), after Q-PAC treatment. At the same time, Q-PAC treatment increased ROS levels in U87 (F(7,33) = 5.03, p < 0.001; Fig. 4e) and RN1 cultures (F(6,28) = 5.76, p = 0.001; Fig. 4e) after 4 h in a concentration-dependent manner.

Discussion

Here, we describe the synthesis of the novel anti-GBM drug Q-PAC and its characterization in vitro. We provide mechanistic evidence that the prodrug Q-PAC undergoes oxidation of its boronate functionality to release the active components QM and 2-PCPA. Our in vitro study shows that Q-PAC: (i) reduces proliferation, migration, invasion, GSH levels and viability of GBM cells; (ii) increases caspase 3/7-mediated apoptosis, intracellular oxidative stress and H3K4 mono- and dimethylation; and (iii) shows a higher potency against GBM cells than healthy astrocytes. We provide the first in vitro evidence for a dual-function strategy of possible LSD1 inhibition and GSH scavenging after activation by H2O2 as a selective treatment avenue against GBM.

The 2-PCPA-based compound Q-PAC impaired several aspects of U87 cells at concentrations as low as 10 μM, while even 300 μM 2-PCPA was ineffective against the immortal GBM cells, despite a similar potency against LSD1. 2-PCPA treatment effects against breast cancer and neuroblastoma cells have been shown by several studies (Schulte et al. 2009; Lim et al. 2010), but required concentrations up to 20-fold higher than the IC50 for 2-PCPA (20.7 μM). Similarly, high concentrations of 2-PCPA have been shown to be ineffective against other immortal GBM cultures, despite high LSD1 protein levels (Singh et al. 2011). Q-PAC not only performed better than 2-PCPA against GBM viability, but also reduced the migration and invasion phenotype of U87 cultures. Aggressive migration and invasion are key treatment challenges of GBM tumours (Demuth and Berens 2004). The suppression of cell migration and invasion following Q-PAC application is thus a promising treatment characteristic of this novel compound. Critically, treatment with the two base components (2-PCPA or QAC) was not effective against U87 cells, highlighting the need for the local activation of the dual-action prodrug Q-PAC.

Considering the marked difference in treatment response of GBM cells to Q-PAC compared with 2-PCPA, we
questioned whether Q-PAC had retained its LSD1 inhibitor function. While the enzymatic assay confirmed the inhibition of LSD1 by Q-PAC, surprisingly, H3K4me1 and H3K4me2 (the primary targets of LSD1 (Lee et al. 2006)) appeared unaffected by Q-PAC treatment in U87 cells. An inverted u-shape concentration-dependent effect on H3K4me1 and H3K4me2 was, however, observed in primary GBM cultures, with the peak difference at 10 μM. One reason for inhibiting LSD1 was to reduce the epigenetic suppression of tumour suppressor genes, as previously shown for LSD1 inhibitors in colorectal cancer (Huang et al. 2009). A reduction in cell proliferation would have been expected but did not occur in U87 or primary GBM cells following Q-PAC treatment as suggested by a lack of an effect on MCM2 (Figure S5c). Together with the limited effect on global H3K4 methylation levels, this finding suggests that Q-PAC causes only minor global methylation changes at these sites, but that H3K9me and gene-specific methylation changes are likely (Schenk et al. 2012; Kidder et al. 2014; Zheng et al. 2015). In addition, LSD1 suppresses tumour suppressor protein 53 (p53) activity (Huang et al. 2007), with loss of LSD1 resulting in reduced colon cancer proliferation (Jin et al. 2013). Q-PAC inhibition of LSD1 could thus result in reduced p53 promoter and protein methylation, enabling p53-mediated apoptosis (Schuler et al. 2000; Scoumanne and Chen 2008), which could be assessed via chromatin immunoprecipitation sequencing in future experiments.

We designed Q-PAC to be activated by H2O2, levels of which are higher in close proximity to GBM cells, and to separate into 2-PCPA and QM. QM reportedly alkylates GSH, preventing its antioxidant function (Hagen et al. 2012; Marzenell et al. 2013). GBM cells up-regulate GSH to compensate for their increased ROS production (Ogunrinu and Sontheimer 2010). Q-PAC and other anti-tumour drugs (including anti-GBM compounds) therefore target this mechanism as a possible treatment avenue (Alexandre et al. 2006; Badr et al. 2013; Kohsaka et al. 2013; Noh et al. 2015). In our mass spectrometry assay, while not being a kinetic assay, we confirmed that prodrug Q-PAC was able to undergo H2O2-induced oxidative cleavage of its boronate

Fig. 4 Quinone methide phenylaminocyclopropane (Q-PAC) triggers apoptosis and oxidative stress in primary glioblastoma (GBM) cells but not healthy astrocytes. Apoptosis of U87 (a), primary human GBM (b) and primary human astrocyte cultures (c) treated with Q-PAC. Apoptosis was quantified through counting of green-fluorescent caspase 3/7 substrates per mm² in microscope images at 20× magnification over time (n = 3 per concentration and culture). (d) Intracellular GSH concentration was quantified via fluorometric assay 4 h after treatment with Q-PAC (0–300 μM) in U87, primary GBM cells (RN1) and primary astrocytes (n = 3 per concentration and cell type). (e) Oxidative stress levels were quantified via a cell-permeant fluorogenic probe 4 h after treatment with Q-PAC (0–300 μM) in U87 and primary GBM cells (RN1), normalized to vehicle-treated cultures (n = 3 per concentration and cell type). Data represent mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared to vehicle control; $$p < 0.01 compared vehicle control (RN1); #$$p < 0.01 compared to vehicle control (U87).
Novel prodrug reduces survival of glioblastoma cells

functionality to QM, 2-PCPA and QM-derived adducts. This was critical given the desired dual action of the drug that required QM to reduce the antioxidant GSH while 2-PCPA simultaneously inhibits LSD1. Our result is consistent with the report of Hagen et al. (2012), who demonstrated a similar breakdown of aminoferrocene-based prodrugs with H$_2$O$_2$. Unlike Hagen et al., however, we were able to directly detect QM, as well as its conjugate addition products. Given the concentration of GSH in cells is higher than the effective concentration of Q-PAC (Khan et al. 2012), the desired reaction between GSH and QM would negate the formation of adducts QMA and therefore reduce the antioxidant ability of the cell. In support of this mechanism, we show that Q-PAC concentration dependently reduces GSH levels in U87 and primary GBM cultures within 4 h of treatment, but not in primary astrocytes. Oxidative stress levels increased within the same treatment timeframe in U87 and primary GBM cells. Similar results have been reported from glioblastoma, prostate and colon cancer cell studies, where GSH scavenger treatment caused a reduction in GSH followed by an increase in ROS levels and apoptosis (Khan et al. 2012; Badr et al. 2013; Noh et al. 2015). Q-PAC treatment likewise resulted in apoptosis, causing a concentration-dependent increase in caspase 3/7 activity in U87 and primary GBM cultures without affecting caspase activity in primary astrocytes. Caspase 3/7 activity increased at Q-PAC concentrations of 10 μM and above, while a 10-fold higher concentration was required for the ROS level increase, indicating that GSH depletion can trigger apoptosis without measurable changes in ROS production (Khan et al. 2012). The lack of any treatment effects following the phenyl ring-free Q-PAC structure (QAC) treatment provides some support for the required combination of LSD1 inhibition and GSH quenching of this hybrid anti-cancer drug. Furthermore, the lack of any 2-PCPA effects on GBM cells, a potent monoamine amine oxidase inhibitor (Yang et al. 2007), suggests that monoamine oxidase inhibition is not the primary mode of action of Q-PAC.

A marked feature of Q-PAC across all culture assays has been the selectivity for GBM cells over healthy astrocytes. The limited effect against healthy astrocytes is likely because of three related differences in comparison to GBM cells: 1) Q-PAC has been designed to be activated by high local H$_2$O$_2$ levels, which are found in the proximity of GBM cells, but not healthy cells (Reuter et al. 2010; Peng and Gandhi 2012); 2) the high metabolic activity of GBM cells results in increased ROS production and heavy reliance on the antioxidant properties of GSH (Ogunrinu and Sontheimer 2010; Noh et al. 2015), making GBM cells highly susceptible to GSH scavenging; and 3) LSD1 expression is higher in GBM cells than healthy cells, as shown in the present and previous studies, increasing the vulnerability to LSD1 inhibitor treatment (Schulte et al. 2009; Singh et al. 2011; Sareddy et al. 2013). While GBM cells would thus be affected by lower LSD1 inhibitor concentrations than healthy cells, irreversible LSD1 inhibitors would nonetheless run the risk of affecting LSD1 function in healthy cells, with cognitive deficits being reported after prolonged administration in mice (Neelamegam et al. 2012). Connecting the LSD1 inhibitor with the GSH scavenging mechanism through an aryl boronate H$_2$O$_2$ activation trigger appears to add a beneficial selectivity layer to Q-PAC. LSD1 inhibitors for lung cancer have progressed to human trials, while preclinical studies with cell and animal GBM models have been of mixed success (Singh et al. 2011; Sareddy et al. 2016), despite high LSD1 expression in the affected tissue. After observing the successful activation of Q-PAC, we evaluated its ability to pass through the blood–brain barrier by calculating the log BB parameter (Clark 1999; Goodwin and Clark 2005). The calculated log BB value for Q-PAC is 0.10, above the ~0.3 cut-off for blood–brain barrier permeability (Rodríguez-Rodríguez et al. 2009), suggesting that Q-PAC will pass through the blood–brain barrier. Our promising work thus needs to be followed up by assessing Q-PAC in xenograft in vivo GBM mouse models for pharmacodynamics and pharmacokinetics as well as further assessing the potential role of 2-PCPA.

In conclusion, we have designed and synthesized a novel prodrug that differs in concept from previous QM-generating prodrugs in that it does not only rely on redox disruption in cancer cells. Rather, Q-PAC targets the redox mechanism of the cancer cells, with a possible role for LSD1 inhibition that is subject to further investigation. We show that Q-PAC reduces viability, migration and invasion, and triggers apoptosis selectively in glioblastoma cells but not healthy astrocytes. Thus, our double-hit strategy exploiting LSD1 inhibition and GSH reduction in GBM forms the first fundamental step for a promising treatment approach.

Author contributions

Conceptualization: C.H., L.O., M.E., Y.S.G.; Methodology: M.E., L.O., Y.S.G., C.H., A.M.; Validation: M.E., C.H., Y.S.G., A.M.; Formal Analysis: M.E., Y.S.G; Investigation: M.E., L.O., C.H., Y.S.G., A.M., D.C., A.H., G.S.; Resources: L.O., C.H., B.H., G.G., B.S.; Writing – Original Draft: M.E., L.O., C.H., Y.S.G.; Writing – Review & Editing: A.M., B.H., B.S.; Visualization: M.E., C.H., Y.S.G.; Supervision: L.O., C.H., M.E.; Project Administration: L.O., C.H.; Funding Acquisition: L.O., C.H.

Acknowledgments and conflict of interest disclosure

We thank Dr Haibo Yu for assistance with calculating the log BB value of Q-PAC. This work was partially supported by a project grant (APP1071250 awarded to LO) from the National Health and Medical Research Council of Australia.
Research Council (NHMRC) and a UOW-ANSTO Joint Seed Project Grant (awarded to LO and CH). LO is supported by an NHMRC Boosting Dementia Research Leadership Fellowship (APP1135720). LO is a handling editor for the Journal of Neurochemistry. The authors declare no further potential conflicts of interest.

ARRIVE guidelines were not followed because no animal work contributed to this manuscript.

Open science badges

This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Practice Disclosures form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Figure S1.** Spectral data confirming the coupling of the two active fragments of the prodrug Q-PAC had taken place.

**Figure S2.** Spectral data confirming the coupling of the two active fragments of the prodrug QAC had taken place.

**Figure S3.** Q-PAC impairs viability and mobility of primary GBM cells but not healthy astrocytes.

**Figure S4.** U87 cells show no response to the constituent parts of Q-PAC.

**Figure S5.** The LSD1 inhibitor Triazole 6 has no effect on viability, confluence or caspase activity of the primary GBM RN1 cells.

**Figure S6.** Q-PAC inhibits LSD1.

**Figure S7.** Prodrug Q-PAC triggers apoptosis and oxidative stress in primary glioblastoma (GBM), without affecting proliferation regulation.

References

Alexandre J., Batteux F., Nicco C., Chéreau C., Laurent A., Guillevin L., Weill B. and Goldwasser F. (2006) Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. *Int. J. Cancer* **119**, 41–48.

Badr C. E., VanHoppe S., Dumbuya H., Tjon-Kon-Fat L.-A. and Tannous B. A. (2013) Targeting cancer cells with the natural compound obtusquinone. *J. Natl Cancer Inst.* **105**, 643–653.

Clark D. E. (1999) Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. *J. Pharm. Sci.* **88**, 815–821.

Day B. W., Stringer B. W., Wilson J. et al. (2013) Glioma surgical aspirate: a viable source of tumor tissue for experimental research. *Cancers* **5**, 357–371.

Demuth T. and Berens M. E. (2004) Molecular mechanisms of glioma cell migration and invasion. *J. Neurooncol.* **70**, 217–228.

Ding J., Zhang Z.-M., Xia Y., Liao G.-Q., Pan Y., Liu S., Zhang Y. and Yan Z.-S. (2013) LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer. *Br. J. Cancer* **109**, 994–1003.

Fiskus W., Sharma S., Shah B., Portier B. P., Devaraj S. G. T., Liu K., Iyer S. P., Bearss D. and Bhalla K. N. (2014) Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. *Leukemia* **28**, 2155–2164.

Forneris F., Binda C., Vanoni M. A., Mattevi A. and Battagliai E. (2005) Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process. *FEBS Lett.* **579**, 2203–2207.

Goodwin J. T. and Clark D. E. (2005) In silico predictions of blood-brain barrier penetration: considerations to “keep in mind”. *J. Pharmacol. Exp. Ther.* **315**, 477–483.

Guillem G., Boussin F. D., Croitoru J., Franck-Duchene M., Le Grand R., Lazarini F. and Dormont D. (1997) Obtention and characterization of primary astrocyte and microglial cultures from adult monkey brains. *J. Neurosci. Res.* **49**, 576–591.

Hagen H., Marzenell P., Jentschz E., Wenz F., Veldwijk M. R. and Mokhir A. (2012) Aminoferrocene-based prodrugs activated by reactive oxygen species. *J. Med. Chem.* **55**, 924–934.

Huang J., Sengupta R., Espejo A. B. et al. (2007) p53 is regulated by the lysine demethylase LSD1. *Nature* **449**, 105–108.

Huang Y., Stewart T. M., Wu Y., Baylin S. B., Martin L. J., Perkins B., Jones R. J., Woster P. M. and Casero R. A. (2009) Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. *Clin. Cancer Res.* **15**, 7217–7228.

Jin L., Hanigan C. L., Wu Y., Wang W., Park B. H., Woster P. M. and Casero R. A. (2013) Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1(DNA methyltransferase 1)-independent manner. *Biochem. J.* **449**, 459–468.

Khan M., Yi F., Rasul A., Li T., Wang N., Gao H., Gao R. and Ma T. (2012) Alantolactone induces apoptosis in glioblastoma cells via GSH depletion, ROS generation, and mitochondrial dysfunction. *IBMB Life* **64**, 783–794.

Kiddler B. L., Hu G. and Zhao K. (2014) KDM5B focuses H3K4 methylation near promoters and enhancers during embryonic stem cell self-renewal and differentiation. *Genome Biol.* **15**, R32.

Kohsaka S., Takahashi K., Wang L., Tanino M., Kimura T., Nishihara H. and Tanaka S. (2013) Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. *Cancer Lett.* **331**, 68–75.

Kumarasinghe I. R. and Woster P. M. (2014) Synthesis and evaluation of novel cyclic Peptide inhibitors of lysine-specific demethylase 1. *ACS Med. Chem. Lett.* **5**, 29–33.

Kutz C. J., Holshouser S. L., Marrow E. A. and Woster P. M. (2014) 3,5-Diaminono-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors. *MedChemComm* **5**, 1863–1870.

Lee M. G., Wynder C., Bochar D. A., Hakimi M.-A., Cooch N. and Shiekhattar R. (2006) Functional interplay between histone lysine demethylase LSD1. *Nature* **449**, 924–934.

Liang G., Lin J. C. Y., Wei V. et al. (2004) Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. *Proc. Natl Acad. Sci. USA* **101**, 7357–7362.

Lim S. D., Sun C., Lambeth J. D., Marshall F., Amin M., Chung L., Petros J. A. and Arnold R. S. (2005) Increased Nox1 and hydrogen peroxide in prostate cancer. *Prostate* **62**, 200–207.

Lim S., Janzer A., Becker A., Zimmer A., Schüle R., Buettner R. and Kirschf J. (2010) Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. *Carcinogenesis* **31**, 512–520.

Liu B., Cheng J., Zhang X., Wang R., Zhang W., Lin H., Xiao X., Cai S., Chen X. and Cheng H. (2010) Global histone modification
patterns as prognostic markers to classify glioma patients. *Cancer Epidemiol. Biomarkers Prev.* **19**, 2888–2896.

Mack S. C., Hubert C. G., Miller T. E., Taylor M. D. and Rich J. N. (2015) An epigenetic gateway to brain tumor cell identity. *Nat. Neurosci.* **19**, 10–19.

Marzenell P., Hagen H., Sellner L., Zenz T., Grünaye R., Pavlov V., Daun S. and Mokhir A. (2013) Aminoferrocene-based prodrugs and their effects on human normal and cancer cells as well as bacterial cells. *J. Med. Chem.* **56**, 6935–6944.

McLendon R. E. and Halperin E. C. (2003) Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? *Cancer* **98**, 1745–1748.

Mohammad H. P., Smitheman K. N., Kamat C. D. et al. (2015) A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. *Cancer Cell* **28**, 57–69.

Murray-Stewart T., Woster P. M. and Casero R. A. (2014) The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue luz sine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines. *Amino Acids* **46**, 585–594.

Neelamegam R., Ricq E. L., Bannister A. J., Sherriff J., Bernstein B., Reuter S., Gupta S. C., Chaturvedi M. M. and Aggarwal B. B. (2010) LSD1 inhibition-triggered release of 4-hydroxytamoxifen. *Nat. Rev. Genet.* **11**, 377–387.

Ota Y., Itoh Y., Kaise A., Ohta K., Endo Y., Masuda M., Sowa Y., Sakai T., Suzuki T., Miyata N., Brenner A. J., Brann D. W. and Vadlamudi R., Zieba M., Suwalski M., Kwiatkowska S., Piasecka G., Grzelewska-Autry S. (2013) Aminoferrocene-based prodrugs and a practical guide. *Prog. Nucl. Magn. Reson. Spectrosc.* **62**, 1616–1618.

Ou H., Cang Y. and Gandhi V. (2012) ROS-activated anticancer prodrugs: a novel therapeutic target for the treatment of glioblastoma. *OncoTarget* **4**, 18–28.

Peng X. and Gandhi V. (2012) Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. *Nat. Med.* **18**, 605–611.

Schneider R., Bannister A. J., Myers F. A., Thorne A. W., Crane-Robinson C. and Kouzaries T. (2004) Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. *Nat. Cell Biol.* **6**, 73–77.

Schuler M., Bossy-Wetzel E., Goldstein J. C., Fitzgerald P. and Green D. R. (2000) p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. *J. Biol. Chem.* **275**, 7337–7342.

Scomanana A. and Chen X. (2008) Protein methylation: a new mechanism of p53 tumor suppressor regulation. *Histol. Histopathol.* **23**, 1143–1149.

Shi Y., Lan F., Matson C., Mulligan P., Whetstine J. R., Cole P. A., Casero R. A. and Shi Y. (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. *Cell* **119**, 941–953.

Singer E., Judkins J., Salomonis N., Matlaf L., Sotropopolus P., McAllister S. and Sorocoeau L. (2015) Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. *Cell Death Dis.* **6**, e1601.

Singh M. M., Manton C. A., Bhat K. P., Tsai W.-W., Aldape K., Barton M. C. and Chandra J. (2011) Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. *Neuro Oncol.* **13**, 894–903.

Suva M. L., Rheinbay E., Gillepsie S. M. et al. (2014) Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. *Cell* **157**, 580–594.

Verhaak R. G. W., Hoadley K. A., Pardem E. et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRα, IDH1, EGFR, and NF1. *Cancer Cell* **17**, 98–110.

Wen L., Chen Y., Zeng L., Zhao F., Li R., Liu Y. and Zhang C. (2012) Triptolide induces cell-cycle arrest and apoptosis of human multiple myeloma cells in vitro via altering expression of histone demethylase LSD1 and JMD2B. *Acta Pharmacol. Sin.* **33**, 109–119.

Williams G. H. and Stoeber K. (2007) Cell cycle markers in clinical oncology. *Curr. Opin. Cell Biol.* **19**, 672–679.

Wray V. (1979) Carbon-carbon coupling constants: a compilation of data and a practical guide. *Prog. Nucl. Magn. Reson. Spectrosc.* **13**, 177–256.

Yang M., Culhane J. C., Szewczuk L. M., Jalioli P., Ball H. L., Machius M., Cole P. A. and Yu H. (2007) Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. *Biochemistry* **46**, 8058–8065.

Zheng Y.-C., Ma J., Wang Z., Li J., Jiang B., Zhou W., Shi X., Wang X., Zhao W. and Liu H.-M. (2015) A systematic review of histone lysine-specific demethylase 1 and its inhibitors. *Med. Res. Rev.* **35**, 1032–1071.

Zieba M., Suwalski M., Kwiatkowska S., Piasecka G., Grzelewskas-Rzymska L, Stolarek R. and Nowak D. (2000) Comparison of hydrogen peroxide generation and the content of lipid peroxidation products in lung cancer tissue and pulmonary parenchyma. *Respir. Med.* **94**, 800–805.
Open Practices Disclosure

Manuscript Title: Novel Dual-Action Prodrug Triggers Apoptosis in Glioblastoma Cells by Releasing a Glutathione Quencher and Lysine-specific Histone Demethylase 1A Inhibitor

Corresponding Author: Lezanne Ooi

Articles accepted to Journal of Neurochemistry after 01.2018 are eligible to earn badges that recognize open scientific practices: publicly available data, material, or preregistered research plans. Please read more about the badges in our author guidelines and Open Science Badges page, and you can also find information on the Open Science Framework wiki.

[X] Please check this box if you are interested in participating.

To apply for one or more badges acknowledging open practices, please check the box(es) corresponding to the desired badge(s) below and provide the information requested in the relevant sections. To qualify for a badge, you must provide a URL, doi, or other permanent path for accessing the specified information in a public, open-access repository. Qualifying public, open-access repositories are committed to preserving data, materials, and/or registered analysis plans and keeping them publicly accessible via the web in perpetuity. Examples include the Open Science Framework (OSF) and the various Dataverse networks. Hundreds of other qualifying data/materials repositories are listed at http://re3data.org/. Preregistration of an analysis plan must take place via a publicly accessible registry system (e.g., OSF, ClinicalTrials.gov or other trial registries in the WHO Registry Network, institutional registration systems). Personal websites and most departmental websites do not qualify as repositories.

Authors who wish to publicly post third-party material in their data, materials, or preregistration plan must have the proper authority or permission agreement in order to do so.

There are circumstances in which it is not possible or advisable to share any or all data, materials, or a research plan publicly. For example, there are cases in which sharing participants' data could violate confidentiality. If you would like your article to include an explanation of such circumstances and/or provide links to any data or materials you have made available—even if not under conditions eligible to earn a badge—you may write an alternative note that will be published in a note in the article. Please check this box if you would like your article to include an alternative note and provide the text of the note below:

[] Alternative note:
[] Open Data Badge

1. Provide the URL, doi, or other permanent path for accessing the data in a public, open-access repository:

[] Confirm that there is sufficient information for an independent researcher to reproduce all of the reported results, including codebook if relevant.

[] Confirm that you have registered the uploaded files so that they are time stamped and cannot be age.

[X] Open Materials Badge

1. Provide the URL, doi, or other permanent path for accessing the materials in a public, open-access repository: all relevant information is provided in the manuscript and custom-made materials will be provided upon reasonable request.

[X] Confirm that there is sufficient information for an independent researcher to reproduce all of the reported methodology.

[] Confirm that you have registered the uploaded files so that they are time stamped and cannot be age.

[] Preregistered Badge

1. Provide the URL, doi, or other permanent path to the registration in a public, open-access repository*:

2. Was the analysis plan registered prior to examination of the data or observing the outcomes? If no, explain.**

3. Were there additional registrations for the study other than the one reported? If yes, provide links and explain.*
No badge will be awarded if (1) is not provided, or if (3) is answered “yes” without strong justification.

If the answer to (2) is “no,” the notation DE (Data Exist) will be added to the badge, indicating that registration postdates realization of the outcomes but predates analysis.

By signing below, authors affirm that the above information is accurate and complete, that any third-party material has been reproduced or otherwise made available only with the permission of the original author or copyright holder, and that publicly posted data do not contain information that would allow individuals to be identified without consent.

Date: 11/12/18

Name: Leanne Ooi

Signature: [Signature]